Abstract
Trigeminal neuralgia (TN) is a severe neuropathic pain disorder characterized by recurrent unilateral, electric shock–like facial pain. The firstly chosen treatments are usually pharmacological therapies. Although, the usage of botulinum toxin (BTX) injections are investigated due to its high levels of safety and effectiveness and low rates of side effects at the same time. This systematic review is focused on an analysis of different studies to confirm the advantages of BTX in the case of TN. In this study there were taken into consideration some randomized controlled trials, prospective studies, open-label studies, and case reports. In total 25 studies were analyzed. The research was focused on the reduction of pain intensity, frequency of recurrence, contentment of patients and rate of side effects. The results showed that BTX-A treatment in TN can be an effective and safe option for the patients. The reduction of pain intensity and frequency of attacks was reported. The findings were supported by some placebo controlled groups. In some cases there was even achieved a complete remission of symptoms. The adverse effects were rare and generally mild and transient. The BTX treatment gave promising results but the long term efficiency should be still investigated. There is also a high need to perform some enlarged studies with standardized procedures of BTX injections which would include the placebo control groups. In conclusion the usage of BTX-A in NT treatment appears to be an effective and safe option and a great alternative to traditional pharmacological therapy.

This publication has 40 references indexed in Scilit: